Some users have developed skin discoloration, cracked skin, and pain where patches were applied
TUESDAY, June 14, 2016 (HealthDay News) — Sales of the migraine treatment skin patch Zecuity (sumatriptan iontophoretic transdermal system) have been halted after patients reported suffering burns and scars where the patches were applied, Teva Pharmaceutical says.
The Israel-based company also said consumers with the disposable battery-powered patches should stop using them, the Associated Press reported.
The patch is designed to deliver a dose of medicine via a single-use, battery-powered patch that is wrapped around the upper arm or thigh. But some users have developed severe redness, skin discoloration, cracked skin, and pain where patches were applied, according to the U.S. Food and Drug Administration.
Teva said it is recalling the patches and working with the FDA to determine the cause of the skin reactions, the AP reported.
Copyright © 2016 HealthDay. All rights reserved.